Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib vs IFN-alpha + Cytarabine in Newly Diagnosed CML-CP (IRIS)
NCT00333840Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2000
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of imatinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Jun 2000; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00333840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333840.